Meet our senior team
Nawab Qizilbash, MBChB MRCP (UK) BSc MSc DPhil (Oxon.)
Senior Clinical Epidemiologist and Director of OXON and:
• Honorary Associate Professor, London School of Hygiene and Tropical Medicine, London University
• Clinical Observer Internal Medicine, Hospitals La Princesa and Cantoblanco, Madrid
• Member of Green Templeton College, Oxford University
• Co-author of x8 Lancet, x1 JAMA and x3 BMJ publications in epidemiology, trials and meta-analysis.
Chief editor of the textbook ‘Evidence-based Dementia Practice’ published by Blackwells, Oxford.
Co-author of chapters on ´Primary Data Collection´and ´Annex 1: Guidance on conducting systematic reviews and meta-analyses of completed comparative pharmacoepidemiological studies of safety outcomes´ In the ENCePP Guide on Methodological Standards in Pharmacoepidemiology published by EMA.
Nawab was Director, Epidemiology and Evidence-based Medicine, GSK (1997-2005); he trained under and worked with Professor Sir Richard Peto F.R.S., and was founding editor of the Cochrane Dementia Group. He also trained in general internal medicine and geriatrics under Professor Sir John Grimley Evans and was Honorary Consultant Physician at the Radcliffe Infirmary, Oxford (1997-2000), and St’s Mary’s Hospital, London (2005-2006).
He was the originator, together with Richard Peto, of the Prospective Studies Collaboration: individual participant data meta-analysis of 61 of the largest prospective cohort studies from 4 continents. Not only that, but he served on the ENCePP Steering Group for 3 years and was an expert for EMA.
Among CROs in Europe, Nawab provides biopharmaceutical sponsors with a unique combination of high quality epidemiological and clinical experience covering many therapeutic areas, to ensure the most optimal and cost-effective studies are conducted. He has sat on many Steering/Scientific committees as an expert in clinical epidemiology.
Steve Albrecht, BSc
Director of Global Strategic Development
Steve Albrecht, has over 29 years of operational experience directing observational studies including compassionate use. He was most recently Global Head of Late Phase for Chiltern International based in London, UK. He has been involved in directing over 150 observational studies including large global registries and retrospective chart studies.
Lorenzo Domínguez, MD MPH
Director of Operations
Lorenzo is a medical doctor and epidemiologist with more than 20 years of experience in conducting observational studies in all major therapeutic areas in Europe.
Lorenzo previously worked as an epidemiologist at AstraZeneca and the global CRO, SGS.
Ignacio Méndez, VMD MPH
Director of Data Analytics & HEOR
Ignacio has more than 19 years of experience in epidemiology, health economics, patient-reported outcomes and associated statistical methodologies.
He specialises in the application and analysis of PROs and health economic measures in observational studies, safety data, and benefit-risk and decision analysis. Ignacio has previously worked at the CRO, TAIS. He was a member of the ENCePP HTA task force of the EMA. He provides advanced statistical expertise.
Marta Mariño, BSc
Marta was previously head of pharmacovigilance at Schering-Plough from 1995-2010 and has experience of all areas and phases of drug safety. She has specialised in the operational, quality and compliance aspects of safety in observational studies and patient registries.
She ensures quality and compliance of all the quantitative safety projects in OXON.
Raúl Sánchez, BSc MSc
Director of Data Management
Raúl has over 22 years of experience in data management using different EDC and paper-based systems in local and international projects in all major therapy areas.
He has previously worked as data manager, SAS programmer, project manager and director of the data management department at Sotio and CROs: ICON and MDS
Our expertise is further boosted by renowned Consultants
(close collaborators on retainers) for involvement in projects as necessary